Lower riskDrug recall · FDA · Published June 4, 2026
Annora Pharma Lacosamide Tablets Recall: Possible Selexipag Mix-Up
Annora Pharma recalls 100mg Lacosamide tablets due to possible mix-up with Selexipag 1000mcg tablets. Check NDC 31722-813-60 and lot numbers A253999/A254000 for affected products.
“Annora Pharma Lacosamide Tablets Recall: Possible Selexipag Mix-Up.” GovInfoNow, updated August 10, 2026. https://govinfonow.com/recall/31217-annora-pharma-lacosamide-tablets-recall-possible-selexipag-mix-up. Based on FDA recall #D-0626-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0626-2026%22&limit=1).
The FDA announced on June 4, 2026, that Annora Pharma Private Limited is recalling Lacosamide Tablets, USP, C V, 100mg due to the presence of foreign Selexipag tablets. Owners should stop using the product immediately.
The recall addresses a possible mix-up where Selexipag 1000 mcg tablets were found in bottles of Lacosamide Tablets USP, 100mg. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show Annora Pharma Private Limited has one other recall on record since February 3, 2026, involving Pitavastatin Tablets with foreign tablets found. Other recent recalls of similar products include Sun Pharmaceutical Perampanel 6mg Tablets Recall (June 17, 2026), Alvogen Thyro-Tabs 150mcg Tablets Recall (December 31, 2025), and Shoolin Pharma Chem Sildenafil Recall (August 3, 2026). FDA's FAERS database contains 18,821 adverse-event reports naming this product, with 16,448 marked serious and 1,871 listing a death.
How to tell if you have this one
Check for NDC code 31722-813-60 on the bottle. Look for lot numbers A253999 or A254000. Products were manufactured for Camber Pharmaceuticals in New Jersey and expire September 30, 2027.
Brand
Annora Pharma
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Look for NDC code 31722-813-60 and lot numbers A253999 or A254000 on the bottle.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 27 days after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0626-2026 (June 4, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0626-2026 to see it in context.
Plain-language summary written by qwen3:4b on August 10, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.